Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile JAK2 V617F
Therapy INCB160058
Indication/Tumor Type myelofibrosis
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
JAK2 V617F myelofibrosis predicted - sensitive INCB160058 Preclinical - Patient cell culture Actionable In a preclinical study, INCB160058 decreased Stat5 phosphorylation, abnormal megakaryopoiesis, and colony formation in human hematopoietic stem cells derived from patients with myelofibrosis harboring JAK2 V617F in culture (Blood (2023) 142 (Supplement 1): 860). detail...
PubMed Id Reference Title Details
Preclinical Evaluation of INCB160058 - a Novel and Potentially Disease-Modifying Therapy for JAK2V617F Mutant Myeloproliferative Neoplasms Full reference...